KeyBanc analyst Thomas Blakey initiated coverage of Nutanix Inc. with an Overweight rating and a $39 price target, suggesting an upside of 38.74 Percent. The recent acceleration, new product cross-sell, and go-to-market partnerships have influenced his above-Street revenue and ACV billings outlook. Blakey further notes that he sees potential rerating with about 50 Percent of revenue from subs…